Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the month of June 2021. The report, dated June 9, 2021, incorporates by reference a press release (Exhibit 99.1) and is part of the company's registration statement on Form F-3.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a cover sheet to incorporate a press release by reference rather than presenting a standalone financial statement.
Material Changes
The filing text does not contain data to compare current performance against prior periods. Material changes, if any, are detailed in the incorporated press release (Exhibit 99.1), the content of which is not included in the provided text.
Guidance, Outlook, and Risks
Management commentary, future guidance, risk factors, and contingencies are not explicitly stated in the provided Form 6-K cover text. These details are expected to be found in the referenced press release dated June 9, 2021.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated June 9, 2021) for the specific news or event triggering this filing.
- Verify the details of the incorporation by reference into Form F-3 (File No. 333-252074).
- Confirm the identity of the signatory, Laure-Hélène Mercier, as the Chief Financial Officer.
- Check subsequent filings for any updates or superseding information regarding the June 2021 report.